### Study Design: LAKE

**Background:** Randomized study to compare the long-term efficacy and safety of efavirenz and lopinavir-ritonavir, each in combination with co-formulated abacavir-lamivudine, in antiretroviral-naïve adults with HIV

**Inclusion Criteria (n = 126)**
- Age ≥18 years
- Antiretroviral-naïve
- No recent opportunistic infection
- No CD4 count or HIV RNA restrictions
- HLA*B5701 testing not available at time of study

**Treatment Arms**
- Efavirenz 600 mg QD + ABC-3TC QD
- Lopinavir-RTV 400/100 mg BID + ABC-3TC QD

---

**Efavirenz + ABC-3TC (n = 321)**

**Lopinavir/r + ABC-3TC (n = 309)**
Efavirenz versus Lopinavir-Ritonavir, with ABC-3TC
LAKE: Results

Week 48: Virologic Response

Efavirenz versus Lopinavir-Ritonavir, with ABC-3TC
LAKE: Results

Week 48: Virologic Response, by Baseline CD4 count (OT analysis)

Conclusions: “Similar virological efficacy was observed for efavirenz and lopinavir/r, when administered with abacavir-lamivudine in antiretroviral-naïve patients, while immunological improvement was slightly superior for efavirenz. The higher rate of discontinuation due to toxicity in the efavirenz group was related to a higher incidence of hypersensitivity reaction. Nowadays, the use of the new formulation of lopinavir/r and the HLA-B*5701 genotype test before starting abacavir should improve the safety profiles of these regimens.”
Acknowledgment

The **National HIV Curriculum** is an AIDS Education and Training Center (AETC) Program supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) as part of an award totaling $800,000 with 0% financed with non-governmental sources. This project is led by the University of Washington’s Infectious Diseases Education and Assessment (IDEA) Program.

*The content in this presentation are those of the author(s) and do not necessarily represent the official views of, nor an endorsement, by HRSA, HHS, or the U.S. Government.*